ALK and non-small cell lung carcinoma: Ipilimumab is an anti-CTLA4 antibody and has been approved independent of PD-L1 status (assessed by a 28-8 pharmDx assay) for the first-line treatment of metastatic NSCLC in patients who do not have a sensitizing EGFR mutation or ALK translocation in combination with nivolumab and 2 cycles of platinum-based chemotherapy.